Publication
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Authors not recorded
Eur J Cancer2015PMID 25542057stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerCutaneous Melanomacivic_curation1.00
- drugDocetaxelcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneNRAScivic_curation1.00
- variantNRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25542057
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRAS Mutation1 | ||||||||
| Docetaxel + TrametinibCombination | Cutaneous MelanomaALIAS | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1225Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four ou… (full text at CIViC) PMID 25542057 · Coupe et al., 2015 · Open in CIViC | civic |